文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

影像引导放疗时代的晚期放射性毒性遗传标记:较低毒性发生率降低骨盆放疗患者γ-H2AX焦点衰减比的预测价值

Genetic markers of late radiation toxicity in the era of image-guided radiotherapy: lower toxicity rates reduce the predictive value of γ-H2AX foci decay ratio in patients undergoing pelvic radiotherapy.
PubMed 文献 · Radiat Oncol · 2024-09-02

本研究纳入88例随访≥24个月的前列腺癌和妇科癌症患者,评估γ-H2AX焦点衰减比(γ-FDR)对晚期放射性毒性的预测价值。医生评估和患者报告的累积≥2级毒性分别为25%和29%,远低于此前队列的51%(CTCAE≥2级);γ-FDR<3.41与中重度毒性发生无关,未能验证γ-FDR作为骨盆放疗患者晚期放射性毒性的预测因子。

要点

  • 医生评估和患者报告的累积≥2级毒性分别为25%和29%,远低于此前队列的51%(CTCAE≥2级)。
  • γ-FDR<3.41与中重度毒性发生无关,未能验证其预测价值。
  • 放疗技术改进使受照膀胱和肠道体积减小,可能降低了毒性发生率。

核心结论

  • 本研究未能验证γ-H2AX焦点衰减比(γ-FDR)作为骨盆放疗患者晚期放射性毒性的预测因子。
  • 放疗技术改进使受照膀胱和肠道体积减小,可能降低了毒性发生率。
  • 未来关于毒性遗传标记的研究应基于这些较低的发生率进行效能计算,并建议除严重程度外还考虑持续存在。

研究设计与样本

  • 纳入前列腺癌和妇科癌症患者,随访≥24个月,共88例。
  • 毒性由医生(CTCAE第4版)和患者(EORTC问卷)评估。
  • γ-FDR在离体照射的淋巴细胞中测定。
  • 采用线性和逻辑回归分析评估γ-FDR与毒性的相关性,使用随访期间记录的最高毒性等级。
  • 通过比较γ-FDR<3.41和≥3.41(此前建立的阈值)患者的生活质量随时间变化,检验总体生活质量与γ-FDR的关联。

主要发现

  • 医生评估和患者报告的累积≥2级毒性分别为25%和29%,远低于此前队列的51%(CTCAE≥2级)。
  • 发生毒性的患者剂量-体积参数较不利;在男性中,这些参数较此前队列显著改善。
  • 低γ-FDR患者比例随毒性严重程度增加而增加,但该趋势未达统计学显著。
  • γ-FDR<3.41与中重度毒性发生无关。
  • 治疗后总体生活质量下降轻微,且γ-FDR<3.41和≥3.41患者相似。

关键数值与推荐

  • γ-FDR阈值3.41为此前建立的阈值。
  • 医生评估的累积≥2级毒性为25%,患者报告为29%。
  • 此前队列中CTCAE≥2级毒性为51%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 低γ-FDR患者比例随毒性严重程度增加的趋势未达统计学显著。
  • γ-FDR<3.41与中重度毒性发生无关,未能验证此前发现。
  • 原文结论指出未来关于毒性遗传标记的研究应基于较低的发生率进行效能计算。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A predictive assay for late radiation toxicity would allow more personalized treatment planning, reducing the burden of toxicity for the more sensitive minority, and improving the therapeutic index for the majority. In a previous study in prostate cancer patients, the γ-H2AX foci decay ratio (γ-FDR) was the strongest predictor of late radiation toxicity. The current study aimed to validate this finding in a more varied group of patients with pelvic cancer. Additionally, the potential correlation between the γ-FDR and patient-reported outcomes was investigated. METHODS: Prostate and gynecological cancer patients with ≥ 24 months of follow-up were included in the current analysis. Toxicity was evaluated by physician (CTCAE version 4) and patient (EORTC questionnaires). γ-FDRs were determined in ex vivo irradiated lymphocytes. Correlation between γ-FDR and toxicity was assessed using both linear and logistic regression analyses. The highest toxicity grade recorded during follow-up was used. The association between global quality of life and γ-FDR was tested by comparing the change in quality of life over time in patients with γ-FDR < or ≥ 3.41, a previously established threshold. RESULTS: Eighty-eight patients were included. Physician-assessed and patient-reported cumulative grade ≥ 2 toxicity was 25% and 29%, respectively; which is much lower than in the previous cohort (i.e., 51% CTCAE grade ≥ 2). Patients with toxicity exhibited less favorable dose-volume parameters. In men, these parameters showed significant improvement compared to the previous cohort. The proportion of patients with a low γ-FDR increased with severity of toxicity, but this trend was not statistically significant. In addition, a γ-FDR < 3.41 was not correlated with the development of moderate to severe toxicity. Post-treatment decline in global quality of life was minimal, and similar for patients with γ-FDR < or ≥ 3.41. CONCLUSIONS: In the present study, the γ-H2AX foci decay ratio could not be validated as a predictor of late radiation toxicity in patients with pelvic cancer. Improved radiotherapy techniques with smaller irradiated bladder and bowel volumes have probably resulted in less toxicities. Future studies on genetic markers of toxicity should be powered on these lower incidences. We further recommend taking persistency, next to severity, into consideration.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Nuijens AC, Oei AL, Koster L, et al. Genetic markers of late radiation toxicity in the era of image-guided radiotherapy: lower toxicity rates reduce the predictive value of γ-H2AX foci decay ratio in patients undergoing pelvic radiotherapy. Radiat Oncol. 2024. PMID: 39223539. doi:10.1186/s13014-024-02501-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。